Japan · Advertising framework
Television advertising for pharmacies and health retail in Japan
General market orientation, not campaign clearance. Research scope and dates
Channel rules
Check the complete consumer-facing message
Regulator guidance
The misleading-representations regime covers goods and services, including misleading impressions about quality or price advantages. Review the full presentation and offer conditions. A truthful individual detail does not justify a deceptive overall claim.
Sources: Establishing Trusted Representation
Advertiser-directed content must be recognisable as advertising
Regulator guidance
CAA’s stealth-marketing rule addresses a supplying advertiser involved in determining a representation whose commercial nature consumers cannot recognise. Assess the brand’s role in the content and the overall presentation, including commissioned posts and reviews.
An influencer acting only as the commissioned publisher is generally not the regulated advertiser under this particular designation; CAA identifies joint supply of the product as an exception. This does not exempt the content from product-advertising law or other duties.
Sources: Stealth marketing regulation from 1 October 2023; CAA — Stealth marketing questions and answers · CAA stealth-marketing FAQ Q1
Review the broadcast execution
Editorial recommendation
Confirm product eligibility for public broadcast and the applicable broadcaster code and clearance process. Review warning timing, speech and image together; internet-video approval does not automatically cover television.
Campaign workflow
Pharmacies & Health Retail: prepare the review
Editorial recommendation
Separate promotion of the pharmacy from advertising of each medicine or other product. Verify online-supply and delivery permissions independently of advertising eligibility. Review price promotions and inducements under both retail and medicine rules.
Keep a traceable campaign decision
Editorial recommendation
Keep one review record linking the offer, local market status, claim evidence, exact creative, media settings and any regulatory or professional clearance. Record who checked each condition. Reopen the review when the offer, claim, source rule or execution changes.
Pre-publication checklist
- Separate promotion of the pharmacy from advertising of each medicine or other product.
- Verify online-supply and delivery permissions independently of advertising eligibility.
- Review price promotions and inducements under both retail and medicine rules.
- Record product or provider eligibility before approving claims.
- Archive the final creative and its evidence, permissions and review decisions.
- Assign an owner for source updates, complaints and prompt withdrawal of inaccurate material.
Scope and unresolved questions
- March 2026 sixth-edition medical advertising examples, website exemption conditions and FFC transitions have been checked. Remaining checks concern prefectural implementation, practitioner-specific and pharmacy requirements, actual product notifications and treatment disclosures, personal-information processing and each messaging technology. This pack does not supply every Japanese mandatory warning text.
- This national baseline does not review every broadcaster rule, platform policy, regional licensing condition, promotion mechanic or data-transfer arrangement. No format-specific warning dimensions or durations should be inferred where none are supplied.
Research scope, introduction and dates
Pharmacy promotion in television campaigns in Japan needs separate decisions about the retailer, the advertised products and any online supply. Use this guide to keep medicine restrictions, seller permissions and promotional price mechanics in the same review.
For television, assess both the creative and the broadcaster's classification of the placement. Presenter choice, voiceover, warning panels and cut-down versions need to work within the same execution; sponsorship and product placement have their own conditions.
General market orientation, not legal, regulatory or medical advice, a complete compliance plan or clearance of an advertisement. Actual requirements depend on the specific offer and campaign.
How to use this national baseline
Editorial overview
This framework combines researched national rules with editorial review steps. Japanese product and medical-service advertising baseline; local and product-specific implementation requires review. A visible channel workflow does not establish that the selected product or service may be advertised there. Read the category restrictions first.
The review date identifies when the cited provisions or regulator excerpts were checked. It does not mean that every local rule, exception, professional standard or platform policy has been reviewed.
Sources
- Establishing Trusted Representation
Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.
- Stealth marketing regulation from 1 October 2023
Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.
- CAA — Stealth marketing questions and answers
Targeted review on 25 October 2026. This date does not certify the currency of other sources or resolve local and campaign-specific requirements.
From framework to action
Local expertise in Japan
Find support with medical and health marketing, marketing and sales advice, or organizing your business and coordinating projects in Japan.
Medical & health marketing
No partners listed in this category yet.
Marketing & sales advisory
No partners listed in this category yet.
Business & project coordination
No partners listed in this category yet.
Join the local partner directory
Would you like your company to be listed?
Talk to us about the terms of a listing. Leave your details and we will get in touch.